We designed the #Onyx benchtop digital genome engineering platform to accelerate the #bioengineering process. Take a peek into the instrument, its custom chemistries, and its intuitive software as it delivers massively parallel #CRISPR based gene editing in bacteria and yeast.
Great article by @johncumbers@Forbes & @TarasavaKatia describing how Inscripta is applying its scalable genome engineering technologies to create the next generation of biobased manufacturing products and processes. #biomanufacturing#syntheticbiology https://t.co/mCtPbE5A7J
We made an exciting announcement from the Advanced Therapies Week conference floor this morning! Check out the news on our site.
https://t.co/eyta22kFIX
Inscripta is thrilled to welcome Infinome Biosciences and Sestina Bio to the team. We have never been more excited about the future of the bioeconomy and how we can create a better way of making products the world needs. https://t.co/4wk1GvY6Nj
#biomanufacturing#bioeconomy
Groundbreaking News! Andrew Horwitz, VP of Research and Development, Sestina Bio, LLC. explains how Inscripta’s #Onyx platform helped accelerate their goals to produce a #sustainable#biomanufacturing process for Bakuchiol!
https://t.co/RIYLAh5gIG
Exciting for Inscripta to join other industry leaders today at The White House Summit on #Biotechnology and #Biomanufacturing for the American #Bioeconomy.
Just the beginning…
https://t.co/UwfSAZlW2N
@InfinomeBio is leading the way in developing innovative solutions for #sustainable#biomanufacturing. Today’s announced partnership with @KalsecInc brings together two tremendous companies!
https://t.co/8OJRQz8Thc
@InfinomeBio is leading the way in developing innovative solutions for sustainable biomanufacturing. Today’s announced partnership with @KalsecInc brings together two tremendous companies!
https://t.co/8OJRQz8lrE
#Diversity of thought breeds #innovation! It takes many seats at the table to drive #success. Read our blog Why Is It Important to Talk About Diversity? to get the facts. https://t.co/WTeyqglXdy
This Sunday is #juneteenth2022. At #Inscripta, we commit ourselves to building a workplace that celebrates inclusion and empowerment. So, we take this time to recognize the contributions of Black Americans in history that have paved the way for equity, equality, and justice.
On June 23rd #Inscripta’s CEO Sri Kosaraju will join other #synbio industry leaders at the 2022 @Barclays Bio-Builders Summit where they will discuss how biology-based manufacturing supports #sustainability & innovation. There is still time to register: https://t.co/vuG16PhgkV
Webinar: Improving Protein Expression in E. coli B-Strains using Rapid Genome Engineering. Dr. Shepherd’s approach enhances speed, precision, and throughput. Sign up today!
https://t.co/lHpg8J0VNm
We are excited to announce that Willow Biosciences onboards the Onyx® Platform to expand strain engineering capabilities and throughput. Read More!
https://t.co/7jluun4Ytz
Inscripta celebrates #pride2022. This month and always, let’s shine a light on diversity, equity, and inclusion by uplifting and supporting #LGBTQIA voices, culture, and rights.
Have you ever tried to produce a protein in a ready-to-use strain & ended up spending months optimizing its expression? Luckily, we've developed a simple way to customize your strain to achieve the best #protein yields. Register for webinar to learn how:
https://t.co/8J2ljF6R9J
Join the next WiSB Women’s Hour – a regular opportunity to learn, share and support women and underrepresented genders in synthetic biology! https://t.co/pBGkNoKmvk
The co-location of the gRNA, edit & barcode on a single construct makes it possible to perform genome-wide editing with thousands of edits in a single experiment and unprecedented efficiency. Learn more about our #Onyx benchtop #genomeengineering platform: https://t.co/eowkg00lFa
@InscriptaInc & @aldevron have signed a licensing agreement for the manufacturing of Inscripta's MAD7™ nuclease. A partnership between two CRISPR pioneers will provide the global scientific community with RUO & GMP-grade MAD7 nuclease. Read the details:
https://t.co/AnvLGK0tyo